Company Overview of Arbor Pharmaceuticals, LLC
Arbor Pharmaceuticals, LLC operates as a specialty pharmaceutical company that develops, manufactures, and commercializes prescription products for cardiovascular and pediatric disorders. Its products include Nitrolingual pumpspray for the acute relief of an attack or the prophylaxis of angina pectoris due to coronary artery disease; EDARBI, an angiotensin II receptor blocker for the treatment of hypertension to lower blood pressure; EDARBYCLOR, an angiotensin II receptor blocker and a thiazide-like diuretic drug that is used for the treatment of hypertension to lower blood pressure; BiDil, a prescription drug for heart disease; GLIADEL Wafer, a drug that is used for the treatment of maligna...
Six Concourse Parkway
Atlanta, GA 30328
Founded in 2006
Key Executives for Arbor Pharmaceuticals, LLC
Founder and Vice President of Commercial Development
Vice President of Finance & Accounting
Vice President of Business Development
Compensation as of Fiscal Year 2014.
Arbor Pharmaceuticals, LLC Key Developments
Arbor Pharmaceuticals, LLC Presents at EBD Group's Biopharm America 2014 Conference, Sep-22-2014
Sep 10 14
Arbor Pharmaceuticals, LLC Presents at EBD Group's Biopharm America 2014 Conference, Sep-22-2014 . Venue: Boston Marriott Copley Place, 110 Huntington Avenue, Boston, MA 02116, United States.
Arbor Pharmaceuticals Announces FDA Acceptance for Filing of its Second NDA
Mar 19 14
Arbor Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has accepted for filing its second New Drug Application (NDA). The NDA was originally filed with the FDA on December 23, 2013 and officially accepted for filing on February 23, 2014. Arbor's first NDA, Nymalize(R) (nimodipine) oral solution, was approved in May of last year. Arbor has a total of seven other branded projects in development consisting of both 505(b)(1) and 505(b)(2) type filings. One of these projects is in phase three clinical development and three are currently in phase two studies. In addition to these NDAs, Arbor has ten Abbreviated New Drug Applications (ANDAs) filed with the FDA through its Wilshire generic division or one of partner companies. Wilshire also has an additional 25 ANDAs in various stages of development. Arbor Pharmaceuticals has been assigned a Prescription Drug User Fee Approval date (PDUFA) of October 23, 2014 for this NDA.
Arbor Pharmaceuticals, LLC Presents at Fourth-Annual Healthcare, Consumer, and Private Equity Conference, Mar-13-2014
Feb 18 14
Arbor Pharmaceuticals, LLC Presents at Fourth-Annual Healthcare, Consumer, and Private Equity Conference, Mar-13-2014 . Venue: Charlotte Country Club. Speakers: Edward Schutter, Chief Executive Officer, President and Director.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|